Last reviewed · How we verify
Isavuconazole (isavuconazole)
At a glance
| Generic name | isavuconazole |
|---|---|
| Sponsor | Pfizer Inc. |
| Therapeutic area | Other |
| Phase | FDA-approved |
| Annual revenue | 349 |
Approved indications
Common side effects
Key clinical trials
- Individualized Precision Isavuconazole Therapy Guided by PK/PD Principles for the Geriatric Population
- A Study of Revumenib in R/R Leukemias Including Those With an MLL/KMT2A Gene Rearrangement or NPM1 Mutation (PHASE1,PHASE2)
- Phase 1 Study of Ibrutinib and Immuno-Chemotherapy Using Temozolomide, Etoposide, Doxil, Dexamethasone, Ibrutinib,Rituximab (TEDDI-R) in Primary CNS Lymphoma (PHASE1)
- Trial of Novel Anti-leukemia Agents in Flu/Mel RIC Transplant for Myeloid Malignancies (PHASE1)
- Imetelstat Combinations in Relapsed AML (PHASE1)
- Temozolomide, Etoposide, Doxil, Dexamethasone, Ibrutinib, and Rituximab (TEDDI-R) in Aggressive B-cell Lymphomas With Secondary Involvement of the Central Nervous System (CNS) (PHASE2)
- Study of Biomarker-Based Treatment of Acute Myeloid Leukemia (PHASE1,PHASE2)
- A Study to Understand How the Use of Paxlovid Affected the Healthcare Use in People With Pre-existing Conditions.
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
| SEC EDGAR | Revenue + earnings |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Isavuconazole CI brief — competitive landscape report
- Isavuconazole updates RSS · CI watch RSS
- Pfizer Inc. portfolio CI